OFI Invest Asset Management Purchases Shares of 317,591 Edwards Lifesciences Co. (NYSE:EW)

OFI Invest Asset Management purchased a new stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 317,591 shares of the medical research company's stock, valued at approximately $22,705,000. OFI Invest Asset Management owned 0.05% of Edwards Lifesciences at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in EW. FSA Wealth Management LLC purchased a new position in Edwards Lifesciences in the third quarter worth $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences in the fourth quarter valued at about $30,000. Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences in the third quarter worth about $32,000. Avior Wealth Management LLC grew its stake in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock worth $35,000 after acquiring an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc acquired a new position in shares of Edwards Lifesciences during the fourth quarter valued at about $46,000. 79.46% of the stock is owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In related news, Director Steven R. Loranger sold 5,739 shares of the company's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company's stock, valued at $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 500 shares of the firm's stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company's stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,303 shares of company stock worth $3,255,356. 1.29% of the stock is currently owned by insiders.

Remove Ads

Analyst Ratings Changes

EW has been the subject of a number of research analyst reports. Citigroup raised their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. The Goldman Sachs Group increased their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday, December 5th. Barclays lifted their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Wolfe Research lowered shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $85.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $79.95.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock traded up $0.13 on Wednesday, hitting $68.52. 4,453,470 shares of the company were exchanged, compared to its average volume of 4,501,923. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $40.28 billion, a price-to-earnings ratio of 9.83, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a 50-day moving average price of $72.03 and a 200 day moving average price of $70.35.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.